文献速递肾血管病与高血压慢性肾脏病

难治性高血压:最新进展综述

Resistant Hypertension: State of the Art Review.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-10-02

动态和家庭血压监测对确认真性难治和识别高危表型至关重要,治疗以优化生活方式和三联 therapy 为基础,首选第四线药物为盐皮质激素受体拮抗剂,CKD患者需特别注意容量状态和血钾风险。

要点

  • 动态和家庭血压监测是确认真性难治性高血压和识别高危表型的关键。
  • 排除假性难治和继发性病因后再升级治疗。
  • CKD患者需仔细评估容量状态、利尿剂选择、肾功能和高钾风险。

核心结论

  • 治疗以优化生活方式和三联 therapy 为基础,首选第四线药物为盐皮质激素受体拮抗剂。
  • 未来管理趋向基于表型的精准治疗,整合动态血压模式、肾素-醛固酮生物学、容量状态、肾功能和心血管代谢合并症。

研究设计与样本

  • 本文为最先进综述(State of the Art Review),检索范围未在摘要中报告。

主要发现

  • 难治性高血压与肥胖、2型糖尿病和CKD常见共存,由醛固酮过多、钠水潴留和交感激活等重叠机制驱动。
  • 动态和家庭血压监测对确认真性难治和识别高危表型(包括夜间高血压和异常血压昼夜节律)至关重要。
  • FDA新批准的aprocitentan和baxdrostat为现有治疗控制不佳的患者提供额外药物选择。
  • 肾去神经术为特定患者提供基于器械的独立方法,研究中的RNA疗法和其他神经调节疗法可能进一步拓宽未来治疗选择。

关键数值与推荐

  • 难治性高血压定义为使用至少三种降压药(含利尿剂)血压仍高于目标,或需四种及以上药物才能控制血压。
  • 指南导向治疗以优化生活方式和三联 therapy(RAS阻断剂、钙通道阻滞剂和噻嗪类利尿剂)为中心,首选第四线药物为盐皮质激素受体拮抗剂。

临床怎么用

  • 使用动态和家庭血压监测确认真性难治性高血压并识别高危表型。
  • 排除假性难治(血压测量不准确、服药不依从、白大衣效应)和继发性病因后再升级治疗。
  • CKD患者需仔细评估容量状态、利尿剂选择、肾功能和高钾风险。

局限性

  • 本文为综述,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistant hypertension, defined as blood pressure above target despite treatment with at least three antihypertensive agents (including a diuretic) or controlled blood pressure requiring four or more medications, affects over 140 million individuals globally and confers increased risks of heart failure, stroke, and chronic kidney disease progression. A considerable proportion of cases represent apparent resistant hypertension, in which pseudo-resistance due to inaccurate blood pressure measurement, medication nonadherence, or white-coat effect has not yet been excluded. Ambulatory and home blood pressure monitoring are therefore central to confirming true resistance and identifying high-risk phenotypes, including nocturnal hypertension and abnormal dipping patterns. Excluding pseudo-resistance and secondary causes remains essential before escalating therapy. Resistant hypertension commonly coexists with obesity, type 2 diabetes, and chronic kidney disease (CKD), and is driven by overlapping mechanisms of aldosterone excess, sodium and water retention, and sympathetic activation. Guideline-directed treatment centers on optimization of lifestyle measures and triple therapy with renin-angiotensin system blockade, a calcium channel blocker, and a thiazide-like diuretic, followed by a mineralocorticoid receptor antagonist as preferred fourth-line agent. In patients with CKD, careful assessment of volume status, diuretic selection, kidney function, and hyperkalemia risk is particularly important. Recent therapeutic advances have expanded options for patients who remain uncontrolled. Newly FDA-approved agents aprocitentan and baxdrostat provide additional pharmacologic options for patients inadequately controlled on existing therapy. Renal denervation offers a separate device-based approach for selected patients, while investigational RNA-based and other neuromodulatory therapies may further broaden future treatment options. Future management is likely to move toward more precise, phenotype-guided treatment integrating ambulatory blood pressure patterns, renin-aldosterone biology, volume status, kidney function, and cardiometabolic comorbidities. Improved diagnostic precision and mechanism-based treatment strategies may reduce persistent treatment gaps and improve long-term cardiovascular and kidney outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Khan MS, Arshad MS, Hall ME, et al. Resistant Hypertension: State of the Art Review. Clin J Am Soc Nephrol. 2026. PMID: 42826060. doi:10.2215/CJN.0000001266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。